Undisclosed ERT/Gene Therapy Programs

About M6P Therapeutics

M6P Therapeutics is a private, preclinical-stage biotech targeting rare Lysosomal Storage Disorders (LSDs) with a novel platform based on mannose 6-phosphate (M6P) biology. The company's S1S3 co-expression platform aims to produce enzyme replacement and gene therapy products with superior lysosomal targeting, potentially improving efficacy over existing treatments. Operating in a high-need, orphan drug space, M6PT is advancing its pipeline with the goal of delivering more effective therapies for patients with limited or no treatment options.

Therapeutic Areas